This report includes an overview of regenerative medicine approaches to treating a variety of cancer types, along with a list of ARM member companies active in developing these therapies, global financings, an overview of the oncology-focused clinical pipeline, as well as commentary from select therapeutic developers active in this area.

Key findings include:

• There are 416 companies worldwide active in developing cell and gene therapies for the treatment of cancer, including 191 clinical stage companies.
• There are 132+ regenerative medicine products in development and 627 clinical trials ongoing for the cancer, including 27 Phase 3 trials.
• Year to date, regenerative medicine companies have raised $621M to develop therapies to treat cancers; in 2018, the sector raised $3.4B.